High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.10B
-0.1%
1.224
+42.36%
1.06B
+1.51%
1.117
+15.15%
1.08B
+1.96%
1.229
+3.29%
Estimates Revision
The market is revising Upward the revenue expectations for Illumina, Inc. (ILMN) for FY2025, with the revenue forecasts being adjusted by 0.61% over the past three months. During the same period, the stock price has changed by 29.41%.
Revenue Estimates for FY2025
Revise Upward
+0.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+4.46%
In Past 3 Month
Stock Price
Go Up
+29.41%
In Past 3 Month
13 Analyst Rating
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 117.77 USD with a low forecast of 80.00 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
5 Hold
3 Sell
Hold
Current: 128.030
Low
80.00
Averages
117.77
High
195.00
Current: 128.030
Low
80.00
Averages
117.77
High
195.00
Piper Sandler
NULL -> Overweight
maintain
$185 -> $195
2025-11-10
Reason
Piper Sandler
Price Target
$185 -> $195
2025-11-10
maintain
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on Illumina to $195 from $185 following quarterly results. The firm keeps an Overweight rating on the shares.
JPMorgan
Neutral
maintain
$100 -> $105
2025-10-31
Reason
JPMorgan
Price Target
$100 -> $105
2025-10-31
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Illumina to $105 from $100 and keeps a Neutral rating on the shares. The company reported a "beat and raise" Q3, the analyst tells investors in a research note.
TD Cowen
Dan Brennan
Hold
maintain
$110 -> $115
2025-10-31
Reason
TD Cowen
Dan Brennan
Price Target
$110 -> $115
2025-10-31
maintain
Hold
Reason
TD Cowen analyst Dan Brennan raised the firm's price target on Illumina to $115 from $110 and keeps a Hold rating on the shares. The firm said they posted a 3Q beat with the upside versus their model largely from better China which was a more moderate decline versus guidance.
Evercore ISI
Vijay Kumar
Outperform
maintain
$132 -> $142
2025-10-31
Reason
Evercore ISI
Vijay Kumar
Price Target
$132 -> $142
2025-10-31
maintain
Outperform
Reason
Evercore ISI analyst Vijay Kumar raised the firm's price target on Illumina to $142 from $132 and keeps an Outperform rating on the shares. Illumina's Q3 performance exceeded expectations with total revenues about 2% above Wall Street estimates, driven by strong operational management and cost efficiencies, the analyst tells investors in a research note. The firm added that challenges in China persist due to export restrictions, impacting instrument revenues by 54%, despite recent approvals to manufacture select instruments locally.
Barclays
Luke Sergott
Underweight
maintain
$95 -> $100
2025-10-31
Reason
Barclays
Luke Sergott
Price Target
$95 -> $100
2025-10-31
maintain
Underweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Illumina to $100 from $95 and keeps an Underweight rating on the shares following the earnings report. The firm sees a lack of visibility into the business.
Canaccord
Hold
maintain
$105 -> $112
2025-10-31
Reason
Canaccord
Price Target
$105 -> $112
2025-10-31
maintain
Hold
Reason
Canaccord raised the firm's price target on Illumina to $112 from $105 and keeps a Hold rating on the shares. The firm said they reported 3Q25 results that were ahead of its estimates and FactSet consensus. The company shipped more NovaSeq X instruments than 2Q25 which was relatively in line with year-earlier levels. Illumina's clinical consumables revenue continued to accelerate, increasing to +12% y/y as clinical customers transition to the NovaSeq X.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Illumina Inc (ILMN.O) is 26.02, compared to its 5-year average forward P/E of 80.74. For a more detailed relative valuation and DCF analysis to assess Illumina Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
80.74
Current PE
26.02
Overvalued PE
133.01
Undervalued PE
28.48
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
40.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
61.51
Undervalued EV/EBITDA
19.19
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
7.47
Current PS
0.00
Overvalued PS
11.46
Undervalued PS
3.47
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ILMN News & Events
Events Timeline
(ET)
2025-11-05
17:18:13
Chinese Commerce Ministry to Remove Export Restrictions on Illumina
2025-10-31 (ET)
2025-10-31
12:00:44
Illumina's Stock Soars by 22.4%
2025-10-30 (ET)
2025-10-30
16:07:45
Illumina increases FY25 adjusted EPS forecast to $4.65-$4.75, up from $4.45-$4.55
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/2e41b134a962263e0694fe0f6c20c876efa410ace7713237715908ad67f37871.jpg)
Preview
4.0
12-04NASDAQ.COMIllumina (ILMN) Upgraded to Strong Buy: Reasons for the Change
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/adc40242f053a0220b2a36170db693e558675eb9f1b8fcd044f1b189f85c97ae.png)
Preview
5.0
11-21TipRanksCathie Wood Acquires Nvidia, ACHR, and Cryptocurrency Stocks While Selling AMD and EXAS
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/c4827927ad7b710fe1ef666cd0a4b397268f9d1b949c2cb21aacc9c88f242d72.png)
Preview
5.0
11-21NewsfilterQuanterix Unveils Leadership and Board Changes to Facilitate Future Growth
Sign Up For More News
People Also Watch
FAQ
What is Illumina Inc (ILMN) stock price today?
What is Illumina Inc (ILMN)'s business?
What is the price predicton of ILMN Stock?
What is Illumina Inc (ILMN)'s revenue for the last quarter?
What is Illumina Inc (ILMN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Illumina Inc (ILMN)'s fundamentals?
How many employees does Illumina Inc (ILMN). have?